This site is intended for Healthcare professionals only.

Non Users of basal Insulin have high risk of hypoglycemia with Beta-blockers


Non Users of basal Insulin have high risk of hypoglycemia with Beta-blockers

The use of beta-blockers among hospitalized basal insulin non-users is associated with higher risk for hypoglycemia, which results in increased hospital mortality, regardless of β-blocker use. However, use of β-blocker can reduce early hypoglycemia-associated mortality risk. The study was presented at  78th Scientific Sessions of American Diabetes Association, held from June 22-26, 2018 in Orlando, Florida.

For the study, the researchers analyzed 13,424 participants, 2648 of whom were administered β-blockers at the start of the study. Patients in this study were not in critical condition and had been receiving insulin subcutaneously for 2 years while being monitored for glucose levels. Hypoglycemia, classified as glucose levels below 70 mg/dL, was stratified into hypoglycemia in the first 24 hours of admission (hypo24), through the length of hospitalization (hypoT), or with glucose less than 40 mg/dL through the length of hospitalization (hypo40).

Read Also: Beta-Blockers enhance mortality risk in Diabetics with CHD : Study

Based on the study, the authors found that:

  • The likelihood of hypo24, hypoT, and hypo40 was greater for those who had received β-blockers (Hypo24 fully adjusted odds ratio [OR] 3.79; 95% CI, 3.21-4.50; P<.0001; HypoT fully adjusted OR 7.70; 95% CI, 6.77-8.77; P<.0001; Hypo40 OR 1.95; 95% CI 1.49-2.57; P<.0001).
  • A higher likelihood of hypoT and hypo40 was associated with non-use of basal insulin but not with use.
  • Hypo24, hypoT, and hypo40 all correlated with higher rates of mortality after adjustments.
  • The use of β-blockers was associated with hypo24 and mortality, but this relationship did not persist at other points.
  • Mortality was increased among non-users vs β-blockers users.

Read Also: Shocking!! Beta Blockers Increase Death, Stroke Risk: Poise Trial at ACC

“[β-blocker] use is associated with higher risk of hypoglycemia in hospitalized basal insulin non-users, but not basal insulin users. Hypoglycemia is associated with increased hospital mortality, regardless of [β-blocker] use, but early hypoglycemia-associated mortality risk is attenuated by [β-blocker] use, concluded the authors.

The following two tabs change content below.
Medha Baranwal

Medha Baranwal

Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She can be contacted at medha@medicaldialogues.in. Contact no. 011-43720751
Source: press release

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted